Marinus Pharmaceuticals Inc said on Monday its experimental treatment for a rare type of genetic epilepsy called CDKL5 deficiency disorder (CDD) met the main goal of reducing seizure frequency in ...

The study assessed OV329 in 68 healthy subjects, comprising 51 individuals receiving active treatment and 17 receiving ...

Most patients with newly diagnosed focal epilepsy face early seizure recurrence, often needing multiple ASM trials to achieve seizure freedom.

A KAIST physician-scientist who identified the cause of refractory epilepsy has successfully achieved a technology export worth 750 billion won by advancing research outcomes into a novel drug ...

First subject received unilateral administration of NRTX-1001 in a new non-MTS cohort; no significant surgical complications ...

For decades, researchers have worked to unravel the mysteries of post-traumatic epilepsy (PTE), a form of epilepsy that ...

Ovid Therapeutics, a Hudson Yards-based drug discovery company, is raising capital to advance the development of medicines to ...